Wall Street brokerages predict that Ritter Pharmaceuticals Inc (NASDAQ:RTTR) will post earnings per share (EPS) of ($0.54) for the current quarter, according to Zacks. Zero analysts have provided estimates for Ritter Pharmaceuticals’ earnings. Ritter Pharmaceuticals reported earnings of ($0.71) per share in the same quarter last year, which would indicate a positive year over year growth rate of 23.9%. The company is scheduled to announce its next quarterly earnings results on Tuesday, August 13th.
On average, analysts expect that Ritter Pharmaceuticals will report full-year earnings of ($1.55) per share for the current financial year. For the next year, analysts expect that the business will post earnings of ($0.65) per share. Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Ritter Pharmaceuticals.
Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.14.
A number of large investors have recently added to or reduced their stakes in RTTR. Virtu Financial LLC bought a new stake in Ritter Pharmaceuticals during the 1st quarter valued at about $46,000. Vanguard Group Inc grew its stake in shares of Ritter Pharmaceuticals by 300.6% in the third quarter. Vanguard Group Inc now owns 56,210 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 42,180 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of Ritter Pharmaceuticals by 264.6% in the first quarter. Renaissance Technologies LLC now owns 128,418 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 93,200 shares during the period. Institutional investors and hedge funds own 9.39% of the company’s stock.
NASDAQ:RTTR traded up $0.01 on Thursday, reaching $0.86. 108,600 shares of the stock traded hands, compared to its average volume of 523,461. The firm has a market cap of $7.69 million, a P/E ratio of -0.23 and a beta of 1.46. Ritter Pharmaceuticals has a 12 month low of $0.47 and a 12 month high of $4.00.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.
Featured Article: Determine Your Level of Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.